Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.

Maryanne M Senna Arash MostaghimiM OhyamaR SinclairY DutroncW S WuG YuC ChiasseriniN SomaniK HolzwarthBrett A King

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)

Baricitinib demonstrated a high level of maintenance of efficacy over 104 weeks in patients with severe AA. Efficacy increased in Week-52 mixed responders, illustrating that long-term treatment is necessary to observe maximum benefit in some patients. No new safety signals were observed.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
early onset
peritoneal dialysis
clinical trial
randomized controlled trial
placebo controlled